Statins for Venous Event Reduction in Patients With Venous Thromboembolism
Status:
Recruiting
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The standard or usual treatment for patients diagnosed with deep vein thrombosis or pulmonary
embolism is treatment with blood thinners (called anticoagulants).
While treatment of blood clots with blood thinners is effective, some research has shown that
adding a statin (medication used to lower cholesterol) may give extra protection. It is
thought that statins can improve how cells along the walls of the vein control inflammation,
which can prevent new blood clots from forming.
The medication in this study, rosuvastatin, is approved in Canada for use as a
cholesterol-lowering medication. The use of rosuvastatin in this study is considered
investigational. This means that Health Canada has not approved the use of rosuvastatin as a
treatment for blood clots. However, it has been approved for use in this research study.
The purpose of this study is to examine if adding a statin (rosuvastatin) to the usual blood
thinner treatment will decrease the risk of another blood clot forming. The investigators
also hope to discover if taking a statin reduces damage to your veins. To do this, some of
the participants in this study will get rosuvastatin and others will receive a placebo (a
substance that looks like the study rosuvastatin but does not have any active or medicinal
ingredients). The placebo in this study is not intended to have any effect on your blood
clot. A placebo is used to make the results of the study more reliable.